BioNTech SE (NASDAQ: BNTX) shares shot up on Wednesday after the company announced, in conjunction with Pfizer Inc. (NYSE: PFE), that its COVID-19 vaccine program was approved in Germany.
Specifically, the German regulatory authority, the Paul-Ehrlich-Institut, has approved the Phase 1/2 clinical trial for BioNTech’s BNT162 vaccine program to prevent COVID-19 infection.
BioNTech and Pfizer are jointly developing BNT162. The trial is the first clinical trial of a COVID-19 vaccine candidate to start in Germany and is part of a global development program. Pfizer and BioNTech also will conduct trials for BNT162 in the United States upon regulatory approval, which is expected shortly.
Separately, BioNTech is also collaborating with Fosun Pharma to develop BNT162 in China, where the companies expect to conduct trials.
Ugur Sahin, CEO and co-founder of BioNTech, commented:
We are pleased to have completed pre-clinical studies in Germany and will soon initiate this first-in-human trial ahead of our expectations. The speed with which we were able to move from the start of the program to trial initiation speaks to the high level of engagement from everyone involved.
Albert Bourla, Pfizer board chair and chief executive, commented:
Pfizer and BioNTech’s partnership has mobilized our collective resources with extraordinary speed in the face of this worldwide challenge. Now that the work in Germany can commence, we are looking forward to and actively preparing for the potential start of this unique and robust clinical study program in the United States in the near future.
BioNTech stock traded up about 14% on Wednesday, at $48.18 in a 52-week range of $12.52 to $105.00. The consensus price target is $38.44.
Pfizer stock was up about 2% to $36.46. The 52-week range is $27.88 to $44.56, and the consensus price target is $41.14.
Travel Cards Are Getting Too Good To Ignore (sponsored)
Credit card companies are pulling out all the stops, with the issuers are offering insane travel rewards and perks.
We’re talking huge sign-up bonuses, points on every purchase, and benefits like lounge access, travel credits, and free hotel nights. For travelers, these rewards can add up to thousands of dollars in flights, upgrades, and luxury experiences every year.
It’s like getting paid to travel — and it’s available to qualified borrowers who know where to look.
We’ve rounded up some of the best travel credit cards on the market. Click here to see the list. Don’t miss these offers — they won’t be this good forever.
Thank you for reading! Have some feedback for us?
Contact the 24/7 Wall St. editorial team.
Latest from 24/7
Our expert who first called NVIDIA in 2009 is predicting 2025 will see a historic AI breakthrough.
You can follow him investing $500,000 of his own money on our top AI stocks for free.